Targeted Therapies for Eosinophilic Gastrointestinal Disorders
The growing recognition of eosinophilic gastrointestinal disorders has revealed the limitations of current treatment (mainly based on dietary modification and corticosteroids), and include refractoriness, high recurrence rates, and the need for long-term therapy. Research efforts, mainly in eosinoph...
Gespeichert in:
| Veröffentlicht in: | BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy biopharmaceuticals, and gene therapy, 2020-08, Vol.34 (4), p.477-493 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 493 |
|---|---|
| container_issue | 4 |
| container_start_page | 477 |
| container_title | BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy |
| container_volume | 34 |
| creator | Lucendo, Alfredo J. López-Sánchez, Piedad |
| description | The growing recognition of eosinophilic gastrointestinal disorders has revealed the limitations of current treatment (mainly based on dietary modification and corticosteroids), and include refractoriness, high recurrence rates, and the need for long-term therapy. Research efforts, mainly in eosinophilic esophagitis (EoE), have unveiled essential pathophysiological mechanisms leading to these disorders, which bear some similarities to those of atopic manifestations and are shared by eosinophilic gastroenteritis (EGE) and eosinophilic colitis (EC). Novel targeted therapies, some imported from bronchial asthma and atopic dermatitis, are currently being assessed in EoE. The most promising are monoclonal antibodies, including those targeting interleukin (IL)-13 (cendakimab) and IL-4 (dupilumab), with phase 3 trials currently ongoing. The potential of anti-integrin therapy (vedolizumab) and Siglec-8 blockers (antolimab) in EGE are also promising. Non-biological therapies for eosinophilic gut disorders, which include preventing the activation of Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and chemoattractant receptor expressed on T helper 2 cells (CRTH2) signaling pathways, and other potential targets that deserve investigation in eosinophilic gut disorders, are reviewed. |
| doi_str_mv | 10.1007/s40259-020-00427-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2408190980</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2431841980</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-4f4179305333867c912f3cfae6bfb58cdc3947207e0affb1b77df63ef1ffbc6b3</originalsourceid><addsrcrecordid>eNp9kEFLwzAYhoMobk7_gAcpePFS_dKkTXsRZM4pDLxM8BbSNNkyumYmLcN_b7ZOBQ-ekpDne_PmQegSwy0GYHeeQpIWMSQQA9CExdsjNMSYFTEu4P14vydxngMdoDPvVwCQkYKdogFJKEtolg7R_Vy4hWpVFc2XyomNUT7S1kUT601jN0tTGxlNhW-dNU2rfGsaUUePxltXKefP0YkWtVcXh3WE3p4m8_FzPHudvowfZrGkFLcx1TTUIpASQvKMyQInmkgtVFbqMs1lJUkRGgFTILQucclYpTOiNA4nmZVkhG763I2zH12owdfGS1XXolG28zyhkIdPFzkE9PoPurKdC613FME5xT2V9JR01nunNN84sxbuk2PgO7u8t8uDXb63y7dh6OoQ3ZVrVf2MfOsMAOkBH66ahXK_b_8T-wXbjYW-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2431841980</pqid></control><display><type>article</type><title>Targeted Therapies for Eosinophilic Gastrointestinal Disorders</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Lucendo, Alfredo J. ; López-Sánchez, Piedad</creator><creatorcontrib>Lucendo, Alfredo J. ; López-Sánchez, Piedad</creatorcontrib><description>The growing recognition of eosinophilic gastrointestinal disorders has revealed the limitations of current treatment (mainly based on dietary modification and corticosteroids), and include refractoriness, high recurrence rates, and the need for long-term therapy. Research efforts, mainly in eosinophilic esophagitis (EoE), have unveiled essential pathophysiological mechanisms leading to these disorders, which bear some similarities to those of atopic manifestations and are shared by eosinophilic gastroenteritis (EGE) and eosinophilic colitis (EC). Novel targeted therapies, some imported from bronchial asthma and atopic dermatitis, are currently being assessed in EoE. The most promising are monoclonal antibodies, including those targeting interleukin (IL)-13 (cendakimab) and IL-4 (dupilumab), with phase 3 trials currently ongoing. The potential of anti-integrin therapy (vedolizumab) and Siglec-8 blockers (antolimab) in EGE are also promising. Non-biological therapies for eosinophilic gut disorders, which include preventing the activation of Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and chemoattractant receptor expressed on T helper 2 cells (CRTH2) signaling pathways, and other potential targets that deserve investigation in eosinophilic gut disorders, are reviewed.</description><identifier>ISSN: 1173-8804</identifier><identifier>EISSN: 1179-190X</identifier><identifier>DOI: 10.1007/s40259-020-00427-w</identifier><identifier>PMID: 32472465</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adrenal Cortex Hormones - chemistry ; Adrenal Cortex Hormones - metabolism ; Allergens ; Antibodies ; Asthma ; Atopic dermatitis ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Clinical Trials, Phase III as Topic ; Colitis ; Corticosteroids ; Cytokines ; Digestive system ; Disease ; Drug dosages ; Dysphagia ; Endoscopy ; Enteritis - therapy ; Eosinophilia - therapy ; Eosinophilic Esophagitis - drug therapy ; Esophageal diseases ; Esophagitis ; Esophagus ; Food ; Gastritis - therapy ; Gastroenteritis ; Gastrointestinal diseases ; Gastrointestinal tract ; Gene expression ; Histology ; Humans ; Inflammation ; Inflammatory bowel disease ; Interleukin 4 ; Janus kinase ; Leukocytes (eosinophilic) ; Molecular Medicine ; Monoclonal antibodies ; Pharmacotherapy ; Review Article ; Steroids ; Transcription</subject><ispartof>BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2020-08, Vol.34 (4), p.477-493</ispartof><rights>Springer Nature Switzerland AG 2020</rights><rights>Copyright Springer Nature B.V. Aug 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-4f4179305333867c912f3cfae6bfb58cdc3947207e0affb1b77df63ef1ffbc6b3</citedby><cites>FETCH-LOGICAL-c441t-4f4179305333867c912f3cfae6bfb58cdc3947207e0affb1b77df63ef1ffbc6b3</cites><orcidid>0000-0002-4473-2399 ; 0000-0003-1183-1072</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40259-020-00427-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40259-020-00427-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32472465$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lucendo, Alfredo J.</creatorcontrib><creatorcontrib>López-Sánchez, Piedad</creatorcontrib><title>Targeted Therapies for Eosinophilic Gastrointestinal Disorders</title><title>BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy</title><addtitle>BioDrugs</addtitle><addtitle>BioDrugs</addtitle><description>The growing recognition of eosinophilic gastrointestinal disorders has revealed the limitations of current treatment (mainly based on dietary modification and corticosteroids), and include refractoriness, high recurrence rates, and the need for long-term therapy. Research efforts, mainly in eosinophilic esophagitis (EoE), have unveiled essential pathophysiological mechanisms leading to these disorders, which bear some similarities to those of atopic manifestations and are shared by eosinophilic gastroenteritis (EGE) and eosinophilic colitis (EC). Novel targeted therapies, some imported from bronchial asthma and atopic dermatitis, are currently being assessed in EoE. The most promising are monoclonal antibodies, including those targeting interleukin (IL)-13 (cendakimab) and IL-4 (dupilumab), with phase 3 trials currently ongoing. The potential of anti-integrin therapy (vedolizumab) and Siglec-8 blockers (antolimab) in EGE are also promising. Non-biological therapies for eosinophilic gut disorders, which include preventing the activation of Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and chemoattractant receptor expressed on T helper 2 cells (CRTH2) signaling pathways, and other potential targets that deserve investigation in eosinophilic gut disorders, are reviewed.</description><subject>Adrenal Cortex Hormones - chemistry</subject><subject>Adrenal Cortex Hormones - metabolism</subject><subject>Allergens</subject><subject>Antibodies</subject><subject>Asthma</subject><subject>Atopic dermatitis</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>Colitis</subject><subject>Corticosteroids</subject><subject>Cytokines</subject><subject>Digestive system</subject><subject>Disease</subject><subject>Drug dosages</subject><subject>Dysphagia</subject><subject>Endoscopy</subject><subject>Enteritis - therapy</subject><subject>Eosinophilia - therapy</subject><subject>Eosinophilic Esophagitis - drug therapy</subject><subject>Esophageal diseases</subject><subject>Esophagitis</subject><subject>Esophagus</subject><subject>Food</subject><subject>Gastritis - therapy</subject><subject>Gastroenteritis</subject><subject>Gastrointestinal diseases</subject><subject>Gastrointestinal tract</subject><subject>Gene expression</subject><subject>Histology</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Inflammatory bowel disease</subject><subject>Interleukin 4</subject><subject>Janus kinase</subject><subject>Leukocytes (eosinophilic)</subject><subject>Molecular Medicine</subject><subject>Monoclonal antibodies</subject><subject>Pharmacotherapy</subject><subject>Review Article</subject><subject>Steroids</subject><subject>Transcription</subject><issn>1173-8804</issn><issn>1179-190X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kEFLwzAYhoMobk7_gAcpePFS_dKkTXsRZM4pDLxM8BbSNNkyumYmLcN_b7ZOBQ-ekpDne_PmQegSwy0GYHeeQpIWMSQQA9CExdsjNMSYFTEu4P14vydxngMdoDPvVwCQkYKdogFJKEtolg7R_Vy4hWpVFc2XyomNUT7S1kUT601jN0tTGxlNhW-dNU2rfGsaUUePxltXKefP0YkWtVcXh3WE3p4m8_FzPHudvowfZrGkFLcx1TTUIpASQvKMyQInmkgtVFbqMs1lJUkRGgFTILQucclYpTOiNA4nmZVkhG763I2zH12owdfGS1XXolG28zyhkIdPFzkE9PoPurKdC613FME5xT2V9JR01nunNN84sxbuk2PgO7u8t8uDXb63y7dh6OoQ3ZVrVf2MfOsMAOkBH66ahXK_b_8T-wXbjYW-</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Lucendo, Alfredo J.</creator><creator>López-Sánchez, Piedad</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4473-2399</orcidid><orcidid>https://orcid.org/0000-0003-1183-1072</orcidid></search><sort><creationdate>20200801</creationdate><title>Targeted Therapies for Eosinophilic Gastrointestinal Disorders</title><author>Lucendo, Alfredo J. ; López-Sánchez, Piedad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-4f4179305333867c912f3cfae6bfb58cdc3947207e0affb1b77df63ef1ffbc6b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adrenal Cortex Hormones - chemistry</topic><topic>Adrenal Cortex Hormones - metabolism</topic><topic>Allergens</topic><topic>Antibodies</topic><topic>Asthma</topic><topic>Atopic dermatitis</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>Colitis</topic><topic>Corticosteroids</topic><topic>Cytokines</topic><topic>Digestive system</topic><topic>Disease</topic><topic>Drug dosages</topic><topic>Dysphagia</topic><topic>Endoscopy</topic><topic>Enteritis - therapy</topic><topic>Eosinophilia - therapy</topic><topic>Eosinophilic Esophagitis - drug therapy</topic><topic>Esophageal diseases</topic><topic>Esophagitis</topic><topic>Esophagus</topic><topic>Food</topic><topic>Gastritis - therapy</topic><topic>Gastroenteritis</topic><topic>Gastrointestinal diseases</topic><topic>Gastrointestinal tract</topic><topic>Gene expression</topic><topic>Histology</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Inflammatory bowel disease</topic><topic>Interleukin 4</topic><topic>Janus kinase</topic><topic>Leukocytes (eosinophilic)</topic><topic>Molecular Medicine</topic><topic>Monoclonal antibodies</topic><topic>Pharmacotherapy</topic><topic>Review Article</topic><topic>Steroids</topic><topic>Transcription</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lucendo, Alfredo J.</creatorcontrib><creatorcontrib>López-Sánchez, Piedad</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lucendo, Alfredo J.</au><au>López-Sánchez, Piedad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeted Therapies for Eosinophilic Gastrointestinal Disorders</atitle><jtitle>BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy</jtitle><stitle>BioDrugs</stitle><addtitle>BioDrugs</addtitle><date>2020-08-01</date><risdate>2020</risdate><volume>34</volume><issue>4</issue><spage>477</spage><epage>493</epage><pages>477-493</pages><issn>1173-8804</issn><eissn>1179-190X</eissn><abstract>The growing recognition of eosinophilic gastrointestinal disorders has revealed the limitations of current treatment (mainly based on dietary modification and corticosteroids), and include refractoriness, high recurrence rates, and the need for long-term therapy. Research efforts, mainly in eosinophilic esophagitis (EoE), have unveiled essential pathophysiological mechanisms leading to these disorders, which bear some similarities to those of atopic manifestations and are shared by eosinophilic gastroenteritis (EGE) and eosinophilic colitis (EC). Novel targeted therapies, some imported from bronchial asthma and atopic dermatitis, are currently being assessed in EoE. The most promising are monoclonal antibodies, including those targeting interleukin (IL)-13 (cendakimab) and IL-4 (dupilumab), with phase 3 trials currently ongoing. The potential of anti-integrin therapy (vedolizumab) and Siglec-8 blockers (antolimab) in EGE are also promising. Non-biological therapies for eosinophilic gut disorders, which include preventing the activation of Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and chemoattractant receptor expressed on T helper 2 cells (CRTH2) signaling pathways, and other potential targets that deserve investigation in eosinophilic gut disorders, are reviewed.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>32472465</pmid><doi>10.1007/s40259-020-00427-w</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0002-4473-2399</orcidid><orcidid>https://orcid.org/0000-0003-1183-1072</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1173-8804 |
| ispartof | BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2020-08, Vol.34 (4), p.477-493 |
| issn | 1173-8804 1179-190X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2408190980 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adrenal Cortex Hormones - chemistry Adrenal Cortex Hormones - metabolism Allergens Antibodies Asthma Atopic dermatitis Biomedical and Life Sciences Biomedicine Cancer Research Clinical Trials, Phase III as Topic Colitis Corticosteroids Cytokines Digestive system Disease Drug dosages Dysphagia Endoscopy Enteritis - therapy Eosinophilia - therapy Eosinophilic Esophagitis - drug therapy Esophageal diseases Esophagitis Esophagus Food Gastritis - therapy Gastroenteritis Gastrointestinal diseases Gastrointestinal tract Gene expression Histology Humans Inflammation Inflammatory bowel disease Interleukin 4 Janus kinase Leukocytes (eosinophilic) Molecular Medicine Monoclonal antibodies Pharmacotherapy Review Article Steroids Transcription |
| title | Targeted Therapies for Eosinophilic Gastrointestinal Disorders |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T08%3A07%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeted%20Therapies%20for%20Eosinophilic%20Gastrointestinal%20Disorders&rft.jtitle=BioDrugs%20:%20clinical%20immunotherapeutics,%20biopharmaceuticals,%20and%20gene%20therapy&rft.au=Lucendo,%20Alfredo%20J.&rft.date=2020-08-01&rft.volume=34&rft.issue=4&rft.spage=477&rft.epage=493&rft.pages=477-493&rft.issn=1173-8804&rft.eissn=1179-190X&rft_id=info:doi/10.1007/s40259-020-00427-w&rft_dat=%3Cproquest_cross%3E2431841980%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2431841980&rft_id=info:pmid/32472465&rfr_iscdi=true |